Comparative Pharmacology
Head-to-head clinical analysis: HARMONYL versus LONITEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARMONYL versus LONITEN.
HARMONYL vs LONITEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
None Documented
None Documented
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Category C
Category C
Antihypertensive
Antihypertensive